Introduction to Easd 2017 Poster 798
Exploring Easd 2017 Poster 798 reveals several interesting facts. Ji Cheol Bae Efficacy and safety of fixed-dose combination therapy of gemigliptin/rosuvastatin compared to each mono therapy in ...
Easd 2017 Poster 798 Comprehensive Overview
Norbert Hermanns Occurrence of severe hypoglycaemic events in the future: analysis of CGM data of the HypoDE study. Alexios Sotiropoulos The effect of ideglira on glycaemic control and cardiometabolic risk factors compared to the non fixed ... Liana Billings Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: ...
Alistair Lumb Effect of insulin degludec on HbA1c, weight and hypoglycaemia: data from the Association of British Clinical ...
Summary & Highlights for Easd 2017 Poster 798
- Richard Pratley Safety and efficacy of ertugliflozin plus sitagliptin vs either treatment alone after 52 wks in patients with type 2 ...
- Geoffrey Rezvani Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on ...
- Yang Du Glycated haemoglobin is increased in critically ill patients with stress hyperglycaemia: implications for risk of diabetes in ...
- Juan Frias Impact of lixisenatide (LIXI) dose range on glycaemic outcomes with fixed-ratio combination iGlarLixi in patients with ...
- Brett Lauring Safety and efficacy of ertugliflozin in combination with sitagliptin in patients with type 2 diabetes inadequately ...
Stay tuned for more updates related to Easd 2017 Poster 798.